Skip to content
Clinical Trials for Alzheimer's Disease

Indianapolis, Indiana

Alzheimer's disease clinical trials in Indianapolis, IN

17 Alzheimer's disease studies are recruiting participants at sites in Indianapolis as of November 16, 2026, according to ClinicalTrials.gov. Clinical Trials for Alzheimer's Disease can help you understand your options and connect with a study team.

Call (888) 927-5895
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Indianapolis at a glance

  • 17 studies are recruiting at a site in Indianapolis.
  • By phase: Phase 1 (1), Phase 1/2 (1), Phase 2 (2), Phase 2/3 (3), Phase 3 (2), Phase 4 (1), No phase (4), Observational (3). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (10), industry (7).
  • Most recent update to one of these records: November 12, 2026.

Studies recruiting in Indianapolis

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Alnylam Pharmaceuticals
    Registry record
    NCT05231785 · updated
  2. Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

    • Phase 2/3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Exciva GmbH
    Study site
    Josephson Wallack Munshower Neurology PC
    Registry record
    NCT07284472 · updated
  3. A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Indiana University Health Neuroscience Center
    Registry record
    NCT07589595 · updated
  4. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    • Phase 3
    • Ages 55 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study sites
    Care Access - South Indianapolis · Josephson Wallack Munshower Neurology, PC
    Registry record
    NCT07602582 · updated
  5. A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

    • Phase 4
    • Ages 50 and older
    • All sexes
    Sponsor
    Alpha Cognition, Inc
    Study site
    Josephson Wallack Munshower Neurology P.C.
    Registry record
    NCT07633470 · updated
  6. A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

    • Phase 2
    • Ages 40 to 55
    • All sexes
    Sponsor
    Alnylam Pharmaceuticals
    Registry record
    NCT07636811 · updated
  7. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

    • Phase 3
    • Ages 60 to 85
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Josephson Wallack Munshower Neurology, PC
    Registry record
    NCT06976203 · updated
  8. Dominantly Inherited Alzheimer Network (DIAN)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Washington University School of Medicine
    Study site
    Indiana University-Indiana Alzheimer Disease Center
    Registry record
    NCT00869817 · updated
  9. Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes

    • No phase
    • Ages 65 and older
    • All sexes
    Sponsor
    Indiana University
    Study site
    Eskenazi Health
    Registry record
    NCT05643144 · updated
  10. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Washington University School of Medicine
    Study site
    Indiana University School of Medicine
    Registry record
    NCT05552157 · updated
  11. A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Washington University School of Medicine
    Study site
    Indiana University School of Medicine
    Registry record
    NCT06647498 · updated
  12. Trial-Ready Cohort-Down Syndrome (TRC-DS)

    • Observational
    • Ages 25 to 55
    • All sexes
    Sponsor
    University of Southern California
    Study site
    Indiana University
    Registry record
    NCT04165109 · updated
  13. Late Onset Alzheimer's Disease

    • Observational
    • Ages 55 and older
    • All sexes
    Sponsor
    Columbia University
    Study site
    NCRAD at Indiana University
    Registry record
    NCT05010603 · updated
  14. Caring for Caregivers of Individuals With Alzheimer's Disease

    • No phase
    • Ages 18 to 99
    • All sexes
    Sponsor
    Indiana University
    Study site
    School of Health and Human Sciences
    Registry record
    NCT07486037 · updated
  15. Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study

    • No phase
    • Ages 40 to 75
    • All sexes
    Sponsor
    Indiana University
    Study site
    Indiana University
    Registry record
    NCT05573490 · updated
  16. Nicotinic Acid for the Treatment of Alzheimer's Disease

    • Phase 1/2
    • Ages 60 to 85
    • All sexes
    Sponsor
    Indiana University
    Study site
    IU Health Neuroscience Center
    Registry record
    NCT06582706 · updated
  17. I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Indiana University
    Study sites
    Community Health Network · IU Health
    Registry record
    NCT05733520 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in Indianapolis, IN on ClinicalTrials.gov.

Ask about studies near Indianapolis

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5895

or send a short form

How should we reach you?

Call